LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

12.6 -4.83

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.6

Máximo

13.53

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.989 49.8
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+51.29% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.3B
Abertura anterior	17.43
Fecho anterior	12.6

Sentimento de Notícias

By Acuity

50%

187 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

14.24 / 14.78 Suporte e Resistência

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mai. de 2026, 23:41 UTC

Ganhos

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 de mai. de 2026, 21:40 UTC

Ganhos

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 de mai. de 2026, 23:12 UTC

Ganhos

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:07 UTC

Ganhos

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 de mai. de 2026, 23:05 UTC

Ganhos

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 de mai. de 2026, 23:04 UTC

Ganhos

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 de mai. de 2026, 22:50 UTC

Ganhos

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 de mai. de 2026, 22:25 UTC

Conversa de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 de mai. de 2026, 22:05 UTC

Conversa de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 de mai. de 2026, 21:58 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:47 UTC

Conversa de Mercado

Ganhos

Costco Posts 13% Sales Growth in April -- Market Talk

6 de mai. de 2026, 21:46 UTC

Ganhos

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 de mai. de 2026, 21:40 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:35 UTC

Conversa de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 de mai. de 2026, 21:32 UTC

Ações em Alta

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 de mai. de 2026, 21:29 UTC

Ganhos

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

51.29% parte superior

Previsão para 12 meses

Média 20 USD 51.29%

Máximo 20 USD

Mínimo 20 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimento

By Acuity

187 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.